<DOC>
	<DOCNO>NCT00732303</DOCNO>
	<brief_summary>Pemetrexed approve second line therapy metastatic NSCLC . Given single-agent activity pemetrexed tolerability pemetrexed combination radiation , study evaluate survival rate toxicities patient poor risk stage III NSCLC .</brief_summary>
	<brief_title>Pemetrexed Radiation Poor-Risk Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Pemetrexed ( Alimta ) 500mg/m2 administer intravenously approximately 10-minutes Day 1 21-day cycle x 3 cycle - Radiation start day -1 2 day 1 cycle 1 . Day 1 radiotherapy must Monday , Tuesday , Wednesday . The planned radiation dose 60 Gy 2.0 Gy fraction . The entire PTV , include primary tumor area know nodal disease , shall receive 60 Gy 2.0 Gy fraction , 5 fractions/week 30 fraction 6 week . Performance Status : ECOG performance status 2 Life Expectancy : Not specify Hematopoietic : - Platelets ≥ 100 K/mm3 - Absolute Neutrophil Count ( ANC ) ≥ 2.0 K/mm3 Hepatic : - Aspartate transaminase ( AST ) ≤ 2.5 x ULN . - Alanine transaminase ( ALT ) ≤ 2.5 x ULN . - Total bilirubin ≤ 1.5 x ULN Renal : - Calculated creatinine clearance ( use Cockcroft-Gault formula ) ≥ 45 cc/min Cardiovascular : - No significant history cardiac disease . Must unstable angina ( anginal symptom rest ) . Pulmonary : - Forced expiratory volume 1 second ( FEV1 ) great 1L</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histological cytological proof Non Small Cell Lung Cancer ( NSCLC ) Measurable nonmeasurable disease per RECIST evaluate image within 28 day prior registration protocol therapy Unresectable Stage IIIA IIIB disease evaluate image within 28 day prior registration protocol therapy Weight loss great 10 % precede six month prior registration protocol therapy . Serum albumin &lt; 0.85 x institutional low limit normal Able willing interrupt nonsteroidal antiinflammatory agent 2 day ( 5 day long act agent piroxicam ) , day , 2 day follow administration pemetrexed Lung V20 &lt; 35 % within 14 day prior registration protocol therapy , plan radiation oncologist Mean lung dose &lt; 20 Gy within 14 day prior registration protocol therapy , plan radiation oncologist Written inform consent HIPAA authorization release personal health information Age ≥ 18 year Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent least 90 day follow completion study treatment . Females childbearing potential must negative pregnancy test within 7 day prior registration protocol therapy . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Patients malignant pleural effusion eligible . The exception patient pleural effusion visible CT scan ( visible CXR ) OR deem small tap.• No CNS metastases . All patient must undergo CT scan/MRI brain within 28 day prior registration protocol therapy exclude brain metastasis . No prior chemotherapy , adjuvant therapy radiotherapy lung cancer . No metastatic disease determine PET scan within 28 day prior registration protocol therapy . No active clinically serious infection judge treat investigator ( &gt; CTC v3 , Grade 2 ) include know human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. No active malignancy . No history collagen vascular disease ( CVD ) . No significant history cardiac disease . Must unstable angina ( anginal symptom rest ) . No history psychiatric illness/social situation would limit compliance study requirement . Females must breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>